Continuous-flow microfluidic process to produce amphotericin B-loaded polymeric nanoparticles for cutaneous leishmaniasis treatment

IF 4.5 3区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Drug Delivery Science and Technology Pub Date : 2025-04-01 DOI:10.1016/j.jddst.2025.106880

Giovanna Cersósimo Nader-Mota , Érika Yoko Suzuki , Maria Paula Gonçalves Borsodi , Tiago Albertini Balbino , Bartira Rossi-Bergmann , Ariane J. Sousa-Batista

{"title":"Continuous-flow microfluidic process to produce amphotericin B-loaded polymeric nanoparticles for cutaneous leishmaniasis treatment","authors":"Giovanna Cersósimo Nader-Mota , Érika Yoko Suzuki , Maria Paula Gonçalves Borsodi , Tiago Albertini Balbino , Bartira Rossi-Bergmann , Ariane J. Sousa-Batista","doi":"10.1016/j.jddst.2025.106880","DOIUrl":null,"url":null,"abstract":"<div><div>High-flow rate 3D microfluidic devices enable controlled nanoparticles (NPs) formation, uniform size and scalable production. However, commercially available chips are expensive and difficult to manufacture. This study developed a low-cost microfluidic device using simple microfabrication techniques. NPs fabrication parameters were optimized to enhance specific characteristics such as particle size and polydispersity index (PDI). The optimized parameters to produce amphotericin B encapsulated NPs (NPs-AmB) included polymer concentration of 10 mg/mL, total flow rate (TFR) of 2000 μg/min, and flow rate ratio (FRR) of 0.225. NPs-AmB demonstrated particle size of 269.0 ± 1.0 nm and PDI of 0.138 ± 0.005. NPs-AmB showed reduced cytotoxicity to macrophages compared to free AmB and exhibited high selectivity towards <em>Leishmania amazonensis</em> promastigotes and amastigotes. The microfluidic device is promising to produce NPs, demonstrating scalability, <em>in vitro</em> safety, and promising anti-leishmanial activity for NPs-AmB.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"108 ","pages":"Article 106880"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Delivery Science and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1773224725002837","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

High-flow rate 3D microfluidic devices enable controlled nanoparticles (NPs) formation, uniform size and scalable production. However, commercially available chips are expensive and difficult to manufacture. This study developed a low-cost microfluidic device using simple microfabrication techniques. NPs fabrication parameters were optimized to enhance specific characteristics such as particle size and polydispersity index (PDI). The optimized parameters to produce amphotericin B encapsulated NPs (NPs-AmB) included polymer concentration of 10 mg/mL, total flow rate (TFR) of 2000 μg/min, and flow rate ratio (FRR) of 0.225. NPs-AmB demonstrated particle size of 269.0 ± 1.0 nm and PDI of 0.138 ± 0.005. NPs-AmB showed reduced cytotoxicity to macrophages compared to free AmB and exhibited high selectivity towards Leishmania amazonensis promastigotes and amastigotes. The microfluidic device is promising to produce NPs, demonstrating scalability, in vitro safety, and promising anti-leishmanial activity for NPs-AmB.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drug Delivery Science and Technology 医学-药学

CiteScore

8.00

自引率

8.00%

发文量

879

审稿时长

94 days

期刊介绍： The Journal of Drug Delivery Science and Technology is an international journal devoted to drug delivery and pharmaceutical technology. The journal covers all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines, gene delivery, tissue engineering, etc. Hot topics, related to manufacturing processes and quality control, are also welcomed.